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Objectives We sought to examine the effects of urocortin (UCN) 2 infusion on hemodynamic status, cardiovascular hor-
mones, and renal function in healthy humans.
Background Urocortin 2 is a vasoactive and cardioprotective peptide belonging to the corticotrophin-releasing factor peptide
family. Recent reports indicate the urocortins exert important effects beyond the hypothalamo-pituitary-adrenal
axis upon cardiovascular and vasohumoral function in health and cardiac disease.
Methods We studied 8 healthy unmedicated men on 3 separate occasions 2 to 5 weeks apart. Subjects received placebo,
25-g low-dose (LD), and 100-g high-dose (HD) of UCN 2 intravenously over the course of 1 h in a single-blind,
placebo-controlled, dose-escalation design. Noninvasive hemodynamic indexes, neurohormones, and renal func-
tion were measured.
Results The administration of UCN 2 dose-dependently increased cardiac output (mean peak increments  SEM)
(placebo 0.5  0.2 l/min; LD 2.1  0.6 l/min; HD 5.0  0.8 l/min; p  0.001), heart rate (placebo 3.3  1.0
beats/min; LD 8.8  1.8 beats/min; HD 17.8  2.1 beats/min; p  0.001), and left ventricular ejection fraction
(placebo 0.6  1.4%; LD 6.6  1.5%; HD 14.1  0.8%; p  0.001) while decreasing systemic vascular resistance
(placebo 128  50 dynes·s/cm5; LD 407  49 dynes·s/cm5; HD 774  133 dynes·s/cm5; p  0.001).
Activation of plasma renin activity (p  0.002), angiotensin II (p  0.001), and norepinephrine (p  0.001)
occurred only with the higher 100-g dose. Subtle decreases in urine volume (p  0.012) and natriuresis
(p  0.001) were observed.
Conclusions Brief intravenous infusions of UCN 2 in healthy humans induced pronounced dose-related increases in cardiac output,
heart rate, and left ventricular ejection fraction while decreasing systemic vascular resistance. Subtle renal effects
and activation of plasma renin, angiotensin II, and norepinephrine (at high-dose only) were observed. These findings
warrant further investigation of the role of UCN 2 in circulatory regulation and its potential therapeutic application in
heart disease. (J Am Coll Cardiol 2007;49:461–71) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.035t
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drocortin (UCN) 2 is a recently discovered vasoactive and
ardioprotective peptide belonging to the corticotrophin-
eleasing factor (CRF) peptide family, which has been
resent throughout vertebrate evolution (1). Recent reports
ndicate the urocortins exert effects beyond the
ypothalamo-pituitary-adrenal axis, directly upon cardiac,
ascular, and vasohumoral function in health and cardiac
isease (2–7). The CRF family of peptides, including CRF
nd UCN 1, 2, and 3, act largely through 2 G protein-coupled
eceptor subtypes, CRF1 and CRF2 (8), and acting in part
rom the Christchurch Cardioendocrine Research Group, Christchurch School of
edicine and Health Sciences, Christchurch, New Zealand. This study was finan-
ially supported by Neurocrine Biosciences Incorporated, the Health Research
ouncil of New Zealand, the National Heart Foundation of New Zealand, and the
anterbury Medical Research Foundation.a
Manuscript received May 22, 2006; revised manuscript received August 7, 2006,
ccepted September 18, 2006.hrough Gs-mediated elevation of cyclic adenosine monophos-
hate, in turn activating cyclic adenosine monophosphate-
ependent protein kinase A. Corticotrophin-releasing factor
redominantly activates CRF1 receptors, and urocortin 1
inds to both CRF1 and CRF2 receptors, whereas UCNs 2
nd 3 are selective agonists for the CRF2 receptors. CRF1
eceptors are found in the brain, pituitary gland, and gut.
here are at least 2 splice variants of the CRF2 receptors,
ermed CRF2(a) and CRF2(b). The CRF2(a) receptor in
umans is found in the central nervous system but
mportantly constitutes the predominant CRF2 receptor
eripherally, particularly in the heart, vasculature, gut,
keletal tissue, and adrenal gland (9,10). In the cardio-
ascular system, CRF2(a) receptors are found in humans
n high concentrations in the left ventricle, intramyocar-
ial blood vessels, and medial layers of internal mammary
rteries (11).
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Urocortin 2 Infusion in Healthy Humans January 30, 2007:461–71Recently, we have shown in
both normal animals and in an
ovine model of pacing-induced
heart failure that UCN 2 dose-
dependently increases cardiac
output and reduces both left
atrial pressure and systemic vas-
cular resistance (SVR) (3). In
intact mice, both wild-type and
in the muscle-specific LIM
protein-deficient heart failure
model, UCN 2 reduced mean
atrial pressure and is positively
inotropic, chronotropic, and lusi-
tropic (6). In the isolated rat
heart, UCN 1, 2, or 3 given
before, during, or after myocar-
dial infarction preserves pump
function and reduces infarct size
(7,12).
Both UCN 1 and 2 suppress
asoconstricting and volume-retaining neurohumoral fac-
ors and enhance renal function in experimental ovine heart
ailure (3,4). In addition, UCN 1 activates the adrenocor-
icotropic hormone (ACTH)-cortisol “stress” response in
ealthy humans and sheep and in patients and sheep with
eart failure—an effect probably mediated by the CRF1
eceptor (4,13–16). Therefore, UCN 1 and 2 appear to have
ignificant effects on cardiovascular function in both normal
ealth and cardiac disease. We hypothesized that, in healthy
umans, UCN 2 would induce the hemodynamic effects
eported for UCN 1 and 2 without stimulation of ACTH
nd cortisol, as seen with UCN 1.
We report the first controlled study in healthy human
olunteers that examines the effects of UCN 2 on hemody-
amic status, echocardiographic parameters, cardiovascular
ormones, and renal function.
ethods
ubjects. We studied 8 healthy unmedicated men ages 24
o 58 years (mean  SD, 41.1  11.7 years), weighing 60
o 104 kg (mean 80  17 kg), with a body mass index 19 to
2 kg/m2 (mean 25.6  4.5 kg/m2), plasma creatinine 0.08
o 0.012 mmol/l (mean 0.098  0.014 mmol/l), and
chocardiographic left ventricular ejection fractions of 58%
o 77% (mean 66.5  7.1%).
tudy protocol. Participants gave written informed con-
ent to the study. The protocol was approved by the Ethics
ommittee of the New Zealand Ministry of Health (Upper
outh B, Canterbury). Human UCN 2 (the 38 amino acid
equence predicted by Reyes et al. [17]) was provided by
eurocrine Biosciences Inc. (San Diego, California) after
anufacture by Bioserv Corporation (San Diego, California).
ubjects were studied using a single-blind dose-escalation
Abbreviations
and Acronyms
A  transmitral diastolic
flow velocity with atrial
contraction
ACTH 
adrenocorticotropic
hormone
Am  diastolic myocardial
velocity during atrial
contraction
CRF  corticotrophin-
releasing factor
E  transmitral early
diastolic flow velocity
Em  early diastolic
myocardial velocity
SVR  systemic vascular
resistance
UCN  urocortinesign, receiving placebo, 25 g, and 100 g of UCN 2 tequentially with a washout period of 2 to 5 weeks between
ach dose. Doses were chosen after a 2-person pilot study
emonstrated measurable effects with no dose-limiting ad-
erse response to the maximum (100 g) dose. On the
orning of the third day of a controlled metabolic diet
sodium 120 mmol/day, potassium 100 mmol/day), subjects
te breakfast and presented to the study room by 7:00 AM. A
4-h urine collection was completed at 8:00 AM. The
ubjects fasted until lunch at 1:00 PM. Participants were
eighed, and 10 ml/kg water was given orally at 8:00 AM
ollowed by 200 ml/h between 9:00 AM and 6:00 PM.
ubjects were seated throughout the day except when
tanding to collect urine samples. At 8:15 AM, venous
annulae were placed in each forearm, one for the infusion
f UCN 2 or placebo and the other for blood sampling. All
ubjects received vehicle placebo (dissolved in 1 ml of water
hen made up to 60 ml in normal saline with 50 ml
dministered), 25 g of UCN 2 (1 mg dissolved in 6.6 ml
f water then 0.2 ml of that solution made up to 60 ml in
ormal saline [0.5 mg/ml] with 50 ml administered), and
nally 100 g of UCN 2 (1 mg of dissolved in 5 ml of water
hen 0.6 ml of that solution made up to 60 ml in normal
aline [2 g/ml] with 50 ml administered) over 1 h,
ommencing at 9:00 AM.
Venous samples were drawn at 8:30 AM, 9:00 AM, 9:30 AM,
0:00 AM, 11:00 AM, 2:00 PM, and 6:00 PM. Blood was
ollected into chilled tubes (containing ethylene diamine
etraacetic acid) for hormone samples except cortisol (hep-
rin) and angiotensin II (0.125 mol/l ethylene diamine
etraacetic acid, 0.05 mol/l o-phenanthroline, 2% ethanol,
.2% neomycin sulfate, and 0.03 mg/ml enalkiren), imme-
iately centrifuged at 4°C, and plasma stored at 80°C
efore assay for UCN 2, cyclic adenosine monophosphate,
yclic guanosine monophosphate, ACTH, cortisol, plasma
enin activity, angiotensin II, aldosterone, arginine vaso-
ressin, N-terminal pro-brain natriuretic peptide, epineph-
ine, norepinephrine, endothelin 1, adrenomedullin, insulin,
nd ghrelin, all according to our published methods (15). At
he conclusion of infusions, serial sampling was conducted
t 10:05, 10:10, 10:15, and 10:20 AM for UCN 2 pharma-
okinetics. Generally, for each hormone, all samples from an
ndividual were analyzed in a single assay. Numbers of UCN
samples were too great to fit into 1 assay, but samples from
he 25-g and 100-g UCN 2 active phases were assayed
ogether. Intra and interassay coefficients of variation, mea-
ured at concentrations similar to those extant during these
xperiments, were all 18.5% except the interassay coeffi-
ient of variation of endothelin-1 at a mean concentration of
.05 pmol/l (25.15%).
Plasma sodium (Na), potassium (K), creatinine, glu-
ose, venous bicarbonate, and chloride (Cl) were measured
t 9:00 AM, 10:00 AM, 11:00 AM, 12:00 PM, 1:00 PM, 2:00 PM,
:00 PM, and 6:00 PM, with additional measurement of
alcium, magnesium, phosphate, total protein, albumin, aspar-
ate transaminase, alanine transaminase, amylase, creatine ki-
n
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January 30, 2007:461–71 Urocortin 2 Infusion in Healthy Humansase, creatine kinase MB fraction, and troponin T at the
:00 AM and 6:00 PM time points.
After blood sampling, subjects stood to collect urine
9:00 AM, 10:00 AM, 11:00 AM, 2:00 PM, and 6:00 PM) for
easurement of volume, cyclic adenosine monophosphate,
yclic guanosine monophosphate, Na, K, and creatinine.
ystolic and diastolic blood pressure, heart rate, and pulse
ximetry were recorded in duplicate at 8:30 AM and every 15
in from 9:00 to 11:00 AM, then hourly until 6:00 PM with
n automatic sphygmomanometer and pulse oximeter (Pro
00 monitor, Dinamap, Wipro GE Healthcare, Bangalore,
ndia). Cardiac output was measured by the thoracic imped-
nce method (Minnesota impedance cardiography, model
04B, Surcom Inc., Minneapolis, Minnesota) every 30 min
rom 8:30 to 11:00 AM, and then hourly until 6:00 PM.
Echocardiography was performed approximately 1 h be-
ore and immediately after infusions with the patient lying
n the left lateral position (using standard techniques with a
ivid 3 echocardiogram (General Electric, Fairfield, Con-
ecticut). Left ventricular volume was measured in the
-chamber view using the modified Simpson’s rule. Data
ere stored digitally for subsequent analysis of left ventric-
lar volumes (diastolic and systolic) and ejection fraction,
ransmitral early diastolic flow velocity (E), transmitral
iastolic flow velocity with atrial contraction (A), decelera-
ion time of the transmitral early diastolic flow velocity,
arly diastolic myocardial velocity (Em), diastolic myocar-
ial velocity during atrial contraction (Am), and systolic
yocardial velocity. Transmitral flow was measured by
ulse-wave Doppler at the mitral valve leaflet tips in the
-chamber view. Tissue Doppler myocardial velocities at
he medial mitral valve annulus were measured using the
achine presets.
Twelve-lead electrocardiograms (Angilent Pagewriter
00, Angilent Technologies, Andover, Massachusetts) were
ecorded at 9:00 AM, 10:00 AM, 2:00 PM, and 6:00 PM. Pulse
ate interval, QRS duration, and QT interval both uncor-
ected and corrected using Fridericia’s method (QT/RR1/3)
ere assessed.
uman UCN 2 two-site enzyme-linked immunosorbent
ssay. Urocortin 2 was measured in heparin plasma with a
-site chemiluminescent enzyme-linked immunosorbent as-
ay using an N-terminal–directed monoclonal antibody for
late coating and a second C-terminal–directed rabbit
olyclonal antibody. Mouse antirabbit IgG-alkaline phos-
hatase conjugate plus CSPD substrate (Applied Biosys-
ems, Foster City, California) were used to generate the
hemiluminescent signal. Full details of the assay have been
ubmitted for publication elsewhere. Dilutions of plasma
amples were parallel to the standard curve. Mean recovery
f UCN 2 added to 6 plasma samples was 107% at 2.43
g/ml and 100% at 1.21 ng/ml and 0.61 ng/ml. The lower
imit of quantitation was 0.3 ng/ml. This was used for
harmacokinetic calculations (as per Food and Drug Ad-
inistration and International Conference for Harmonisa-ion guidelines). The assay detection limit (upper 95% aonfidence interval [CI] for the zero standard) was 0.11
g/ml (n 36). In studies with multiple samples, valid data
an be obtained below the assay limit of quantitation
ecause the number of samples allows valid statistical
omparison. We have therefore used all assay data for
tatistical calculations and reported 95% CI. The intra- and
inter)-assay coefficients of variation (n  36) were 5.0%
5.7%) at 0.68 ng/ml, 2.8% (5.7%) at 1.34 ng/ml, and 2.8%
3.9%) at 2.45 ng/ml.
Cross-reactivity was determined by measurement of hu-
an UCN 1, UCN 3, and CRF at 510, 670, and 500 ng/ml,
espectively, all evoking assay responses that were at or less
han the limit of quantitation (0.3 ng/ml). Urocortin 1 and
RF responses also were at or less than the 95% CI for the
ero standard.
tatistics. Data were analyzed by repeated-measures anal-
sis of variance using SPSS version 11.5 statistical package
SPSS Inc., Chicago, Illinois). The significance reported is
he time by dose interaction unless otherwise stated (dose
ffect). Where significant differences between doses were
dentified, these were further explored using paired compar-
sons between doses (i.e., the Fisher least significant differ-
nce test). Analyses for study days included measurements
ssessed from the commencement of infusion to the last
ample of the day unless otherwise stated. UCN 2 half-life
t1/2), metabolic clearance rate, and volume of distribution
ere calculated using a 1-compartment model during and
fter the infusion period (WinNonLin Professional 3.1,
harsight Corporation, Mountain View, California). Hor-
onal data were consistently non-normally distributed and
ere loge transformed before analyses, which adequately
ormalized distributions for parametric analysis. Geometric
eans and 95% CIs are reported for these measures. Results
ther than those for hormones are presented as mean 
EM. To aid clarity, pooled 95% CIs are displayed for the
raphed hormones and pooled SEM for the graphed he-
odynamics. A value of p  0.05 was taken to indicate
tatistical significance.
esults
reinfusion hormone, biochemical, and hemodynamic
ariables did not differ between the 3 experimental days
placebo, 25 g, and 100 g UCN 2). Hemoglobin
ecreased during the course of the study period (placebo:
46.7  3.7 g/l; 25 g: 143.5  4.7 g/l; 100 g: 138.7 
.7 g/l; p  0.004) secondary to sampling 813 ml of
lood over the approximately 6-week course of the study.
nfusion of UCN 2. Plasma UCN 2 concentrations in-
reased in dose-related fashion compared with time-
atched placebo concentrations with 25 g (0.09 [95% CI
.05 to 0.17] to 1.28 [1.08 to 1.52] ng/ml) and 100 g
nfusions (0.09 [95% CI 0.05 to 0.17] to 5.69 [4.48 to 7.23]
g/ml; p  0.001 for both doses). Peak concentrations were
chieved at the end of the 1-h infusions. Plasma cyclic
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Urocortin 2 Infusion in Healthy Humans January 30, 2007:461–71denosine monophosphate tended to increase (p  0.056),
nd cyclic guanosine monophosphate clearly was increased
p  0.009) by UCN 2 infusions (Fig. 1).
harmacokinetics. Pharmacokinetics were consistent with
1-compartment model. The t1/2 for immunoreactive
CN 2 (95% CI) was 10.1 (9.0 to 11.2) min with an
etabolic clearance rate of 0.37 (0.31 to 0.43) l/min and a
olume of distribution of 5.2 (4.5 to 5.9) l.
emodynamics and echocardiography. The administra-
ion of UCN 2 induced dose-related increases in cardiac
utput (maximal increments from preinfusion levels were
.5  0.2, 2.1  0.6, and 5.0  0.8 l/min for placebo,
5 g, and 100 g, respectively; p 0.001). Corresponding
ncrements in heart rate were 3.3  1.0, 8.8  1.8, and
7.8  2.1 beats/min (p 0.001). The administration of
CN 2 decreased diastolic blood pressure (maximal
ecrements were 4.9  1.2, 7.4  1.5, and 14.1 
.1 mm Hg; p 0.001) and mean arterial pressure (4.3
Figure 1 Plasma UCN 2, cAMP, and cGMP Responses to UCN
Plasma urocortin 2 (UCN 2), cyclic adenosine monophosphate (cAMP), and cyclic g
(geometric mean and pooled 95% confidence intervals) to UCN 2 infusion in 8 hea.5, 5.5  1.8, and 10.2  2.0 mm Hg; p  0.01), but eot systolic blood pressure—with overall increases in pulse
ressure of 6.4  0.6, 10.6  3.0, and 18.5  2.1 mm Hg
p 0.001). Systemic vascular resistance decreased128
0, 407  49, and 774  133 dynes·s/cm5 (p  0.001).
ustained postinfusion decreases in diastolic blood pres-
ure and mean arterial pressure were observed on both
ctive days compared with placebo (analysis of variance
nalysis by group; diastolic blood pressure: 25 g, p 
.011; 100 g, p  0.034; mean arterial pressure, 25 g,
 0.014; 100 g, p  0.037). After a provision of lunch
t 1:00 PM (4 h after the commencement of infusions), we
bserved transitory increases in cardiac output, heart rate,
ystolic blood pressure, and pulse pressure with decreases in
iastolic blood pressure, mean arterial pressure and SVR (Figs.
and 3).
Dose-related increases in left ventricular ejection fraction
p  0.001), E (p  0.019), Em (p  0.041), and systolic
yocardial velocity (p  0.001) were observed, whereas
sion
ine monophosphate (cGMP) responses
en.2 Infu
uanos
lthy mnd-systolic volume (p  0.001) decreased. No significant
c
d
w
i
N
s
a
c
b
w
d
0
c
a
a
N
e
a
n
r
s
a
w
(
P
p
c
a
a
s
U
b
(
465JACC Vol. 49, No. 4, 2007 Davis et al.
January 30, 2007:461–71 Urocortin 2 Infusion in Healthy Humanshanges were observed in end-diastolic volume (p  0.808),
eceleration time (p  0.743), or E/Em (p  0.808),
hereas A (p  0.054) and Am (p  0.062) tended to
ncrease (Figs. 4 and 5).
eurohormones. The 100 g dose of UCN 2 induced
ignificant increases in plasma renin activity (p  0.001),
ngiotensin II (p  0.002), norepinephrine (p  0.001),
yclic guanosine monophosphate (p  0.005), and
lunted the increase in epinephrine observed compared
ith placebo (p  0.034). Aldosterone also increased
uring the 2 h from commencement of infusion (p 
.031) (Fig. 6). A sustained postinfusion increase in
yclic guanosine monophosphate was observed on both
ctive days compared with placebo (analysis of variance
nalysis by group; 25 g, p  0.023; 100 g, p  0.042).
eurohormonal spikes were all within normal ranges
Figure 2 Cardiac Output, Heart Rate, and Systemic Vascular R
Cardiac output, heart rate, and systemic vascular resistance responses (mean and
standard errors) to urocortin (UCN) 2 infusion in 8 healthy men. Lunch was given axcept for UCN 2, where the normal range is unknown, (nd plasma renin activity and angiotensin II where the
ormal ranges are 0.4 to 2.3 nmol/l/h and 6 to 26 pmol/l,
espectively. Adrenocorticotropic hormone, cortisol, in-
ulin, ghrelin, N-terminal pro-brain natriuretic peptide,
rginine vasopressin, endothelin 1, or adrenomedullin
ere not significantly altered by either dose of UCN 2
results not shown).
lasma biochemistry. The infusion of UCN 2 did not alter
lasma Na, K, creatinine, glucose, venous bicarbonate, Cl,
alcium, magnesium, phosphate, total protein, albumin,
spartate transaminase, alanine transaminase, amylase, cre-
tine kinase, creatine kinase-MB, or troponin T (results not
hown).
rinalysis. The administration of UCN 2 induced subtle
ut significant dose-related decreases in urinary volume
p  0.012), excretion of sodium (p  0.001), potassium
nce Responses to UCN 2 Infusion
d
e 4-h observations.esista
poole
fter thp  0.001), and creatinine (p  0.024) (Fig. 7).
E
c
c
O
i
h
o
f
m
p
1
s
w
466 Davis et al. JACC Vol. 49, No. 4, 2007
Urocortin 2 Infusion in Healthy Humans January 30, 2007:461–71lectrocardiogram. The administration of UCN 2 did not
hange pulse rate interval, QRS duration, QT interval, or
orrected QT interval.
bserved events. All volunteers experienced flushing dur-
ng active infusions of UCN 2, which subsided within an
our of the end of infusions. Four subjects had the sensation
Figure 3 Systolic, Mean Arterial, and Diastolic Blood Pressure an
Systolic, mean arterial, and diastolic blood pressure and pulse pressure response
to urocortin (UCN) 2 infusion in 8 healthy men. Lunch was given after the 4-h obsef increased heart rate during active infusions. In addition, iour subjects had mild and transient hypokalemia (nadir 3.3
mol/l) on active days after eating lunch, coinciding with
ostprandial increases in insulin, which also was seen in
person on the placebo day (nadir 3.4 mmol/l). Two
ubjects felt dizzy upon intravenous needle insertion, 1 of
ho fainted subsequently (at the end of high-dose
se Pressure Responses to UCN 2 Infusion
n and pooled standard errors)
ns.d Pul
s (mea
rvationfusion). Among these water-loaded subjects, 2 exhib-
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467JACC Vol. 49, No. 4, 2007 Davis et al.
January 30, 2007:461–71 Urocortin 2 Infusion in Healthy Humansted mild and transient hyponatremia on active days
nadir 133 mmol/l) also seen in 2 on placebo days (nadir
33 mmol/l). One volunteer had mild headache, 1 had
norexia in the evening after a high-dose infusion, and 1
ad mild transient hyperamylasemia recorded at 6:00 PM
38 U/l at 9:00 AM to 96 U/l [normal range 8 to 53 U/l])
n the day of high-dose infusion with resolution when
etested 3 days later.
iscussion
e provide the first report on the biological effects of UCN
infused in healthy humans. Brief intravenous infusions of
5 and 100 g of UCN 2 markedly increased measured
lasma UCN 2, and pharmacokinetic measurements indi-
ated a half-life of 10.1 min with a volume of distribution of
.2 l. The administration of UCN 2 had clear effects on
emodynamic status with more subtle neurohormonal and
enal actions.
emodynamic status. The impressive dose-related in-
rease in cardiac output is in large part the result of
ecreased after-load through vasodilation (as evidenced
y the large decreases in SVR and the flushing in all
ubjects at both doses) with some contribution from
ncreased heart rate. Whether the increase in heart rate
eflects a direct effect of UCN 2 or is purely baroreflex-
ediated is unknown. Increased cardiac output counter-
alanced the effect of the vasodilatory response on sys-
olic pressures, the net result being minimal change in
ystolic blood pressure compared with clear decreases in
iastolic blood pressure. The echocardiographic findings
Figure 4 LVEDV, LVESV, and LVEF
Responses to UCN 2 Infusion
Left ventricular end-diastolic volume (LVEDV), end-systolic volume (LVESV), and
ejection fraction (LVEF) responses (mean  SEM) to urocortin (UCN) 2 infusion
in 8 healthy men.re consistent with augmented left ventricular systolicunction with dose-related decreases in end-systolic vol-
me and increases in ejection fraction and systolic mitral
alve tissue velocity. Comment on inotropism must be
eserved because loading conditions and heart rate were
ot fixed; however, UCN 2 has a positive inotropic effect
n the isolated mouse heart as does UCN 1 in sheep (2,6).
irect effects on myocardial relaxation were not mea-
ured, but the dose-related increase in Em would be
Figure 5 E, Em, E/Em, and Sm Mitral Valve
Tissue Velocity Responses to UCN 2 Infusion
Transmitral early diastolic flow velocity (E), early diastolic myocardial tissue
velocity at the medial mitral valve annulus (Em), E/Em, and systolic myocardial
(Sm) mitral valve tissue velocity responses (mean  SEM) to urocortin (UCN) 2
infusion in 8 healthy men.
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Urocortin 2 Infusion in Healthy Humans January 30, 2007:461–71onsistent with enhanced relaxation, an effect seen also in
solated mouse heart (6), the mechanism of which is
nclear. A limitation of our echocardiographic data is its
onblinded interpretation.
It is likely UCN 2 vasodilates by both endothelial nitric
xide/cyclic guanosine monophosphate-dependent and
independent mechanisms as seen with UCN 1 (5).
ndothelium-independent vasodilation also has been dem-
nstrated with the administration of UCN 2 (11). It is
ossible that the significant increase in cyclic guanosine
onophosphate noted is related to nitric oxide and not
Figure 6 PRA, Angiotensin II, Aldosterone, Epinephrine, and No
Plasma renin activity (PRA), angiotensin II, aldosterone, epinephrine, and norepine
(geometric mean and pooled 95% confidence intervals) responses to urocortin (UCikely to be from natriuretic peptides because we saw no cncrease in N-terminal pro-brain natriuretic peptide,
lthough atrial natriuretic peptide was not measured. The
ustained decreases in diastolic blood pressure and re-
uced mean atrial pressure on active days may be medi-
ted by a cyclic guanosine monophosphate-dependent
echanism given its concurrent elevation, but other
ntermediary mechanisms we have not identified also may
lay a part. The absence of a cardiac natriuretic peptide
esponse in the face of pronounced effects on cardiac
utput, heart rate, and arterial pressure suggests either
he effects of UCN 2 produce no net increment in
ephrine Responses to UCN 2 Infusion
nfusion in 8 healthy men.repin
phrine
N) 2 iardiomyocyte strain or that increased natriuretic peptide
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eptide clearance.
In previous studies, we observed no hemodynamic re-
ponse to administration of 50 g of UCN 1 in normal
ubjects or patients with heart failure, despite UCN 1
aving a similar affinity as UCN 2 for the CRF2 receptor
8). This result may be because of the CRF binding protein,
hich binds UCN 1 but not UCN 2 (18), potentially
educing in vivo UCN 1 availability to the receptor. This
ypothesis is supported by peak plasma levels induced by 50
g of UCN 1 in a similar group of healthy humans being
ess than that of 25 g of UCN 2, given the molecular
eights of the 2 peptides are similar as were the weights of
he subjects studied (13).
eurohormones. The lack of an ACTH-cortisol or
stress” response to UCN 2 is in striking contrast to our
Figure 7 Urine Volumes and Excretion of Sodium, Potassium, a
Urine volumes and excretion of sodium, potassium, and creatinine (mean  SEM)revious experience with UCN 1 administered to humans r13,14). It supports the hypothesis that the pituitary-adrenal
xis effects of the urocortins are mediated by CRF1 receptors
nd, therefore, will not be induced by UCN 2 because of its
ack of affinity for this receptor.
Notably, increments in renin, angiotensin II, and norepi-
ephrine were observed only at the higher (100 g) dose of
CN 2, which is suggestive of a secondary effect mediated
y hemodynamic changes (i.e., decrease in SVR) exceeding
certain threshold. The increase in plasma norepinephrine
ay reflect baroceptor-mediated increments in sympathetic
raffic. Renin increases in response to decreased afferent
rterial pressure and flow, changes in delivery of sodium to
he macula densa, and to increased sympathetic traffic to
drenoceptors on the juxtaglomerular cells. It is likely a
ecrease in renal perfusion pressure and/or increased sym-
athetic drive, at least partially, underlies the pronounced
reatinine Responses to UCN 2 Infusion
nses to urocortin (UCN) 2 infusion in 8 healthy men.nd C
respoise in renin with high-dose UCN 2. Clarification of
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Urocortin 2 Infusion in Healthy Humans January 30, 2007:461–71hether or not UCN 2 exerts a more direct effect on renin
ecretion may require in vitro experiments.
The increase in an angiotensin II presumably reflects the
ncrease in renin, and the trend toward increased aldoste-
one (at high doses of UCN 2) is a plausible response to the
pike in plasma angiotensin II. Our work in normal sheep
licited no change in plasma renin activity or aldosterone to
CN 2 infusions, but the decreases in mean arterial pressure
nd SVR were comparatively smaller (3). Regional hemo-
ynamic studies in rats that were given intravenous bolus
oses of UCN 2 showed little or no change in renal vascular
onductance (19). There is a paucity of work looking at the
ffect of UCN 2 on renal cellular activity.
We observed divergent plasma catecholamine responses
ith stimulation of norepinephrine and subtle, relative
uppression of epinephrine. The CRF2 receptors in the
drenal medulla mediate norepinephrine secretion in rat
haeochromocytomas cell lines (10). However, our data
ermit no conclusions on possible direct effects of UCN 2
n catecholamine release from the adrenal or elsewhere.
enal function. The effects of UCN 2 on renal function,
lthough statistically significant, were generally modest.
ur results do not allow conclusions on the underlying
echanisms. One of the clearest effects was on sodium
xcretion, which fell in a dose-related fashion, which may be
he net effect of reductions in renal perfusion pressure,
ogether with increments in renin, angiotensin II, and
ldosterone (at least at the higher dose of UCN 2) and
ympathetically mediated changes in intrarenal vasomotor
one. These all occurred in the absence of any increment in
irculating cardiac natriuretic peptide levels. Potassium
xcretion also was reduced, presumably secondary to the
forementioned factors. Further clarification might be pro-
ided by experiments in the isolated perfused kidney and by
loser study of possible direct effects on glomerular mesan-
ium, renal tubular function, and juxtaglomerular cells.
harmacokinetics. The 10-min half-life of UCN 2 in
ealthy humans is shorter than that of UCN 1, which we
ave previously reported (i.e., 52 min) (13). The volume of
istribution was approximately that of plasma volume indi-
ectly supporting lack of binding to the CRF-binding
rotein, cell membrane binding, or lipid solubility. The
echanism of clearance has yet to be established.
onclusions. In this first report of UCN 2 administered
o healthy humans, this peptide induced marked dose-
elated increases in cardiac output, heart rate, and left
entricular ejection fraction with decreased SVR. Lus-
tropism is suggested by the dose-related increase in Em.
he activation of renin, angiotensin II, and norepineph-
ine occurred only with the greater (i.e., 100 g) dose,
ith its more powerful hemodynamic effects. It remains
nclear whether these neurohormonal responses purely
eflect a secondary response to hemodynamic perturba-
ion or are partly the result of direct effects of UCN 2 on
he kidney and/or adrenal. The decrease in urine sodium
xcretion and more modest changes in urine volume,otassium, and creatinine may be partially secondary to
educed renal perfusion pressure and increased renal
ympathetic traffic but, again, possible direct renal effects
f UCN 2 warrant investigation.
Urocortin 2 has powerful cardiac actions in healthy
umans and in experimental (ovine) heart failure. The
eurohormonal activation and modest decrease in sodium
xcretion observed in our current report are largely consis-
ent with findings in normal sheep and contrast with the
ronounced suppression of volume-retaining vasoconstric-
or neurohormonal systems, and augmentation of renal
unction observed in experimental ovine heart failure (3),
hich suggests the response to exogenous UCN 2 is
ependent on the neurohumoral and hemodynamic milieu
nto which it is introduced. Natriuretic and neurohormone-
uppressing effects may only be unmasked in settings with
ctivation of powerful volume- and sodium-retaining mech-
nisms as in heart failure. Taken together, experimental and
he human preclinical studies to date warrant further inves-
igation of the role of UCN 2 in circulatory regulation and
otential therapeutic effects in human heart failure or a
alignant hypertension/hypertensive crisis.
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